Alembic receives USFDA final approval for Paroxetine Extended-Release Tablets
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Paroxetine extended-release tablets are indicated for the treatment of major depressive disorder
Paroxetine Extended-Release Tablets USP, 25 mg and 37.5 mg, are indicated for the treatment of major depressive disorder
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
Subscribe To Our Newsletter & Stay Updated